The Consolidated Appropriations Act, 2023, signed December 29, 2022, eliminated the DATA-Waiver requirement, commonly called the X-waiver, that had governed which practitioners could prescribe buprenorphine for opioid use disorder. Any practitioner holding a current DEA registration with Schedule III authority can now prescribe buprenorphine for OUD without a separate waiver number or a cap on patient counts. The repeal changed who can write the prescription. It did not touch the recordkeeping, training attestation, and corresponding responsibility rules that govern how a pharmacy fills that prescription and defends it in an audit.
The DATA-Waiver Requirement Eliminated by the 2023 Act
Section 1262 of the Act, the Mainstreaming Addiction Treatment provision, struck the requirement under 21 U.S.C. 823(g)(2) that a practitioner obtain a separate DATA-Waiver registration, sometimes called an "X" DEA number, before prescribing buprenorphine for OUD. The prior 30, 100, and 275 patient-count caps and the certification tied to counseling and ancillary-service capacity are gone with it. The DEA confirmed the change in a January 2023 letter to registrants: a standard registration with Schedule III authority is now the only credential a prescription for buprenorphine requires. The change reaches every practitioner type eligible for that authority, including physicians, nurse practitioners, and physician assistants, so long as state scope-of-practice law also permits the prescribing.
The MATE Act's Eight-Hour Training Requirement
A separate provision, the Medication Access and Training Expansion Act, put a new obligation in the X-waiver's place. Beginning June 27, 2023, any practitioner applying for a new or renewed DEA registration with controlled substance authority, veterinarians excepted, must attest to completing eight hours of one-time training on the treatment and management of patients with opioid or other substance use disorders. Per DEA's own MATE Act guidance, a practitioner already registered before June 27, 2023 satisfies the attestation at the next scheduled renewal falling on or after that date, not retroactively. Training certificates are kept by the practitioner and are not submitted to DEA at application.
What Did Not Change: Corresponding Responsibility and Recordkeeping
The waiver repeal did not touch the pharmacist's corresponding responsibility duty under 21 CFR 1306.04, which requires an independent judgment that a controlled substance prescription is issued for a legitimate medical purpose in the usual course of professional practice, regardless of the prescriber's registration status. General controlled substance recordkeeping under 21 CFR Part 1304, the three-year DEA registration renewal cycle, and a pharmacy's own suspicious order monitoring and inventory reconciliation obligations are also unaffected. A wider pool of eligible prescribers can mean higher buprenorphine dispensing volume at the pharmacy counter, which raises the practical stakes of the audit-ready recordkeeping a DEA inspection or a PBM audit will test. A pharmacy that treats the repeal as a general loosening of controlled substance oversight, rather than as a narrower change limited to prescriber eligibility, is the pharmacy most likely to have a finding turn into a registration action.
The X-waiver controlled who could prescribe buprenorphine. It never controlled who could safely dispense it, and that duty still rests with the pharmacist on every fill.
Why Early Legal Counsel Is Critical
It is critical that a pharmacy or a prescriber promptly retain experienced healthcare defense counsel upon receiving a DEA inspection notice, a subpoena, or any inquiry tied to buprenorphine dispensing patterns, before the matter escalates toward a DEA order to show cause or a contested registration renewal denial. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, and preserve relevant defenses while counsel communicates with investigators on the pharmacy's behalf. Delaying legal representation can affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies and practitioners in DEA inspections, registration disputes, and recordkeeping audits tied to controlled substance dispensing, including buprenorphine. If your pharmacy is facing a DEA inspection, a registration renewal dispute, or an audit finding connected to buprenorphine dispensing volume, contact us for a free, confidential consultation.
